Overview

• The Connexus implant was placed and removed in about 20 minutes during a May 14 University of Michigan epilepsy surgery, successfully capturing neural activity without adverse effects.
• The fully implantable system uses 420 microelectrodes pushed into brain tissue and wirelessly transmits data to an under-the-skin transceiver.
• Paradromics will seek regulatory approval to launch a clinical trial later this year to study the device’s long-term safety and efficacy in humans.
• The company aims to decode neural signals into synthesized speech, text and cursor control to restore communication for patients with paralysis from ALS, stroke or spinal cord injury.
• This milestone advances Paradromics into the clinical stage alongside competitors Neuralink, Synchron and Precision Neuroscience in the race to commercialize high-resolution BCIs.